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Cytokine single nucleotide polymorphisms and intrarenal gene In recent years single nucleotide polymorphisms (SNPs)
expression in chronic allograft nephropathy in children. have become of increasing interest because of their possi-
Background. Single nucleotide polymorphisms (SNPs) have ble association with certain disease states. In transplanta-been reported to influence cytokine production. Certain cyto-
tion, SNPs in cytokine genes have been reported to indi-kine high producer genotypes have been associated with an
cate a higher risk for acute rejection and chronic allograftincreased risk for acute rejection and chronic allograft dysfunc-
tion (CAD) after transplantation. Our study evaluates SNP dysfunction (CAD) by several groups [1, 2]. Genotyping
distribution for transforming growth factor-1 (TGF-1), in- of transforming growth factor-1 (TGF-1), interleukin-
terleukin-10 (IL-10), and tumor necrosis factor- (TNF-) in 10 (IL-10), and tumor necrosis factor- (TNF-) SNPs
pediatric renal transplant recipients and control individuals and
has been suggested in order to establish predictive mark-correlates them to corresponding intrarenal gene expression.
ers for the posttransplant course in individual patients.Methods. SNPs for TGF-1 (codon 10 and 25), IL-10 (posi-
tions –1082, 819, 592) and TNF- (position 308) were TGF- is a multifactorial cytokine that initiates and
determined in 30 patients with stable graft function, in 75 pa- terminates tissue repair and its sustained production regu-
tients with CAD, and in 173 control individuals by allele-spe- lates the development of tissue fibrosis [3]. It has also been
cific polymerase chain reaction (PCR). Intrarenal cytokine associated with the promotion of renal allograft intersti-gene expression was studied in 25 biopsies with chronic allo-
tial fibrosis and thereby chronic allograft nephropathygraft nephropathy (CAN) and 27 normal kidney specimens by
(CAN) [4, 5]. Two SNPs in the first exon of TGF-1,real-time reverse transcription (RT)-PCR.
Results. No difference in allele and genotype frequency was the best evaluated isoform of this gene, have been de-
detected in any of the investigated groups. No correlation be- scribed at position 869 (T/C) and at position 915
tween genotype and intragraft cytokine gene expression was (G/C). These polymorphisms result in the change of co-recognized in CAN patients. However, in normal kidney speci-
don 10 from leucine (T) to proline (C) and in the changemens, the low producer TGF-1 genotype at codon 10 was
of codon 25 from arginine (G) to proline (C) [6]. In vitro,associated with significant lower TGF-1 mRNA expression.
This association was not found for IL-10 or TNF-. the presence of leucine or arginine, respectively, has been
Conclusion. Our results do not support the proposition that shown to lead to a higher production of TGF-1 [1, 7].
certain specific cytokine genotypes for TGF-1, IL-10, and IL-10 is an anti-inflammatory cytokine but may pro-
TNF- are associated with CAD. Intrarenal cytokine gene
mote antibody responses by its stimulatory effect on Bexpression only correlated to one TGF-1 SNP in normal kid-
cells. Three SNPs in the promotor region of IL-10 areney specimens. Since overall TGF-1 expression was higher
in transplanted patients compared to controls, this suggests most commonly studied in the context of transplantation:
that SNPs may not play a significant role once the immune Positions –1082 (G/A), –819 (C/T) and –592 (C/A) up-
system is activated. stream from the transcriptional start site [8]. The pres-
ence of an “A” at 1082 and at 592 has been related
to low IL-10 production in cultured cells [7–10]. This
low producer allele has been correlated with increased
incidence of rejection in heart and kidney graft recipients
in some studies [11, 12] but not in others [13–15]. InKey words: TGF-1, IL-10, TNF-, single nucleotide polymorphisms,
chronic allograft nephropathy, pediatric transplantation. fact, one group described the presence of high-producing
IL-10 genotype as a risk factor for higher incidence andReceived for publication October 24, 2002
severity of acute rejection [15]. The same group foundand in revised form January 30, 2002
Accepted for publication February 24, 2003 that the high-producing IL-10 genotype might have long-
term protection in kidney transplantation [16]. 2003 by the International Society of Nephrology
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TNF- is a potent proinflammatory cytokine. Most phenolate mofetil as rescue therapy (abstract; Henne
et al, Am J Transplant 1: 150, 2001). Blood for cytokinecommonly studied is the SNP at 308 that involves a
G/A substitution [17]. It has been shown that an “A” at polymorphism typing was taken at any time after trans-
plantation. Snap-frozen sections of renal biopsies hadposition –308 was associated with increased transcription
and production of TNF- [18, 19]. Patients with either been collected prospectively at one of the participating
centers (Hannover Medical School, Hannover) betweenrenal or cardiac transplants and the high-producing
TNF- genotype were found to be at increased risk for January 1997 and December 1999 for gene expression
analysis. We were able to determine intragraft cytokinerejection [11, 14, 15, 20].
The literature on cytokine polymorphisms and their expression in 25 biopsies diagnosed with CAN.
importance on long-term graft survival is heterogeneous.
ControlsIn addition, the relationship between cytokine SNPs and
cytokine production is based on in vitro studies. Apart Umbilical cord blood was used for determination of
cytokine polymorphisms (Cpoly) in 173 newborns bornfrom a single case report on two patients [21], no study
has tried to combine SNP cytokine data with intragraft at the neonatal unit of Hannover Medical School, Han-
nover, to serve as controls for distribution of polymor-cytokine expression. In the present study, our aim was to
evaluate the significance of polymorphisms in the coding phisms in Germany.
Twenty-eight renal cortex specimens (Cex) derivedregion of TGF-1 and in the promotor regions of IL-10
and TNF- for long-term graft survival. We assessed whe- from nephrectomies due to renal cell carcinoma served
as controls for intrarenal cytokine expression [22, 23].ther the so-called high-producing genotypes are more
frequent in our pediatric patient collective with CAD as Macroscopically tumor-free kidney was used to separate
cortex from medulla and samples were snap-frozen incompared to patients with stable graft function or normal
control subjects. Furthermore, in vivo intrarenal cyto- liquid nitrogen prior to storage and subsequent RNA
extraction. Sections from immediate vicinity of thesekine production in transplant biopsies with CAN and
normal control kidney specimens was compared to the samples were taken for routine histology, stained, and
reviewed for the absence of neoplasma, inflammation,underlying genotype.
and changes greater than expected with age [22].
METHODS Ethics approval
Patients The study protocol was approved by the Institutional
Review Board of the Hannover Medical School, Hanno-All recipients of renal transplants presenting to the
outpatient clinic (Departments of Pediatric Nephrology, ver, Germany (Decision #2054).
Hannover Medical School, Hannover, and Charite´, Ber-
Cytokine polymorphisms analysislin, Germany) between May 1999 and April 2000 were
asked to participate and follow-up was performed until Genomic DNA from whole blood or renal tissue was
obtained using the DNeasy Kit (QIAGEN, Hilden, Ger-July 2002. Of these patients, 105 were selected for this
study: 30 patients with stable graft function, which was many) following the instructions of the manufacturer.
All samples were analyzed for two polymorphisms indefined as no or less than five percent change in their
glomerular filtration rate (GFR) per year, and 75 patients the TGF-1 coding region at position 869 (codon 10)
and 915 (codon 25), for three polymorphisms in thewith chronic deterioration of their graft function [chronic
allograft dysfunction (CAD)], including 42 with biospy- IL-10 promotor region at position 1082, 819 and
592 and for one polymorphism in the TNF- promotorproven CAN. Patients had been transplanted between
April 1983 and May 1999, with mean follow-up time of region at position 308. For detection of all polymor-
phisms, the Cytokine Typing PCR-SSP Tray Kit (Collabo-8.9 (4.4) years for stable and 8.5 (3.6) years for CAD.
Sixty-six (stable, N 16; CAD, N 50) patients received rative Transplant Study, Heidelberg, Germany) was used
according to the manufacturer’s instructions. Cyclinga cadaveric transplant and 39 (stable, N  14; CAD,
N  25) patients had a living related donor transplanta- conditions were as follows: 94C for 2 minutes; 10 cycles
at 94C for 10 seconds, and 65C for 1 minute; 20 cyclestion. At the time of transplantation, the patients were
between 1 to 16 years old (stable, 8.6  4.4 years; CAD, at 94C for 10 seconds, 61C for 50 seconds, and 72C
for 30 seconds. All polymerase chain reactions (PCRs)9.2  4.3 years) and 54% were male recipients (stable,
N  14 males and 16 females; CAD, N  43 males and were performed on a Perkin Elmer 9600 Thermal Cycler
(Perkin Elmer, Rodgau, Germany).32 females). All patients were on a similar immunosup-
pressive regimen, including cyclosporine A (adjusted to
Cytokine expression analysisa target through level of 150  50 ng/mL) and predniso-
lone (4 mg/m2) and azathioprine (2 mg/kg). After CAN- Ten percent of a core biopsy cylinder was cut and
snap-frozen in liquid nitrogen. Total RNA was extractedconfirming biopsy, 40 patients were switched to myco-
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Table 1. Absolute numbers and percentages for transformingusing the RNeasy Kit (QIAGEN) after initial homogeni-
growth factor-1 (TGF-1), interleukin 10 (IL-10) and tumor
zation. Reverse transcription (RT) was performed using necrosis factor- (TNF-) genotypes frequencies in pediatric renal
transplant recipients with stable function and chronic allograftrandom hexamer primers (Roche, Mannheim, Germany)
dysfunction (CAD) and control individualsand Moloney-murine leukemia virus (MMLV) (Life Tech-
nologies, Gibco BRL, Eggenstein, Germany) as pre- Cpoly Stable CAD Cex
viously described [23]. Quantitative real-time PCR to Alleles N % N % N % N %
detect TGF-1, IL-10, and TNF- gene expression was
TGF-1
performed on an ABIPrism SDS 7700 TaqMan (Applied codon 10
TT 67 39 8 27 29 39 6 21Biosystems, Weiterstadt, Germany) using predeveloped
TC 83 48 22 73 39 52 16 58assay reagents (PDAR) (Applied Biosystems) according
CC 23 13 0 0 7 9 6 21
to the standard protocol supplied by the manufacturer. codon 25
GG 151 87 27 90 68 91 23 82All samples were measured in triplicate. Positive and
GC 22 13 3 10 7 9 5 18negative controls were included with each run. Relative
CC 0 0 0 0 0 0 0 0
quantification of gene expression was performed by nor- IL-10
1082malization to the housekeeping gene glyceraldehyde-3-
GG 28 16 7 23 8 11 4 14phosphate dehydrogenase (GAPDH) after determining
GA 81 47 12 40 42 56 18 64
the first cycle of fluorescent detection (threshold cycle) AA 64 37 11 37 25 33 6 22
819 and 592and calculating the differences of these threshold cycles
CC and CC 97 56 17 57 31 41 15 53(delta threshold cycle method) as described earlier [23].
CT and CA 67 39 9 30 33 44 10 36
TT and AA 9 5 4 13 11 15 3 11
Statistical analysis TNF-
AA 10 6 1 3 1 1 2 7Statistical analysis was performed using SPSS. For
AG 31 18 7 23 24 32 9 32
comparison of allele and genotype frequencies the chi- GG 132 76 22 74 50 67 17 61
square test was used. The level of significance was cor- Abbreviations are: Cpoly, control group for single nucleotide polymorphisms
(SNPs) cytokines; Cex, control group for cytokine expression. No statisticallyrected for the number of SNP examined for each cyto-
significant differences occurred.kine (Bonferroni correction for multiple comparisons).
Cytokine expression was compared using Mann-Whitney
U test for comparison of two and Kruskal-Wallis test
for comparison of three groups. (N  38) of stable and G allele in 95% (N  143) of
CAD and in 95% (N  57) of stable; IL-10, G allele in
39% (N  58) of CAD and in 43% (N  26) of stable
RESULTS
and C alleles in 63% (N 95) of CAD and in 72% (N 
SNPs for TGF-1, IL-10, and TNF- 43) of stable; TNF-, A allele in 17% (N  26) of CAD
and in 15% (N  9) of stable. In particular, there was noHigh-producing phenotypes have been suggested for
TGF-1 in case of the homozygous presence of the T significant difference between CAD and stable patients.
We analyzed the genotype distribution for the threeallele at codon 10 or the G allele at codon 25; for IL-10 in
case of homozygosity for G, C, and C alleles at positions cytokines and corresponding six SNPs (Table 1). For
TGF-1 codon 10, most individuals were either homozy-1082, 819, and –592, respectively; and for TNF- in
case of the A allele at position 308. For TGF-1 and gous or heterozygous for the T allele (i.e., most individu-
als should show either a high or an intermediate producerIL-10, for which we analyzed more than one SNP, this
results in the following high-producer haplotypes: phenotype). When distribution for stable and CAD pa-
tients was compared with normal controls and to eachTG/TG and GCC/GCC.
Allelic distribution for TGF-1 showed that two thirds other, no significant differences were observed. How-
ever, none of the stable patients had homozygous pres-of normal individuals (63%, N  217) had the T allele
at codon 10 and 94% (N  324) had the G allele at ence of the C allele at TGF-1 codon 10 that would result
in a low-producing phenotype. Genotypes for TGF-1codon 25. For IL-10 at position –1082, the G allele was
found in 40% (N  137) of normal control individuals. codon 25 were either homozygous (GG) or heterozygous
(GC) for G with the homozygous genotype being mostAs previously described [13, 24], SNPs at position 819
and –592 for IL-10 were linked in all individuals leading common (Cpoly, 87%). The homozygous genotype CC
was not found in any group. Comparison of all groupsto CC and TA haplotypes, respectively. Seventy-five per-
cent (N  261) of control individuals had the CC haplo- revealed no significant differences. In the case of the
IL-10 SNP at –1082, the majority of normal control indi-type. The A allele for TNF- was found in 15% (N 
51) of control individuals. The similar allelic distributions viduals turned out to be heterozygous (GA  47%)
followed by being homozygous for A (37%) and for Gwere seen in patients with CAD and stable patients:
TGF-1, T allele in 65% (N  97) of CAD and in 63% (16%). The same ranking was found when we looked at
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stable and CAD patients. However, the CAD patient
group had the lowest percentage of homozygous GG
genotype (11% as compared to 16% in Cpoly and 23%
in stable) that would be associated with high-producing
phenotype. None of the comparisons reached statistical
significance. Most control individuals were homozygous
(CC and CC  56%) or heterozygous (CT and CA 
39%) for the IL-10 alleles at positions 819 and –592.
The similar distribution was seen for stable and CAD
patients, with CAD patients having the highest percent-
age of TT and AA genotypes (15% as compared to 5%
in Cpoly and 13% in stable) that would result in low
IL-10 production. None of these slight differences were
statistical significant after correction for multiple com-
parisons. Control individuals presented with either a
TNF- homozygous (76%) or heterozygous (18%) G al-
lele at position –308, the homozygous presence of A was
rare (6%). Comparison of both patients groups with the
controls and with each other showed the similar dis-
tribution pattern and no significant differences. Most
CAD patients belonged to the group of intermediate
producers.
Haplotype frequencies for TGF-1 and IL-10 were
analyzed accordingly (data not shown) and no significant
differences were found.
Fig. 1. Intrarenal transforming growth factor (TGF-1) mRNA ex-Intrarenal cytokine expression of TGF-1, IL-10,
pression for pediatric renal transplant recipients with chronic allograftand TNF- nephropathy (CAN) (N  25) () and control individuals (N  28)
() for TGF-1 codon 10 (A) and TGF-1 codon 25 (B). OverallIntrarenal cytokine expression was measured by quan-
(ALL) TGF-1 expression was different between CAN and controls.titative real time PCR in 25 graft biopsies of patients *P  0.05 for the comparison with controls. However, for the different
with CAN and 28 normal renal Cex. TGF-1 genotypes and their predicted producing phenotypes (High,
Intermediate, Low) only the comparison between Low vs. High forAllelic and genotype distribution for this second con-
codon 10 in controls resulted in a significant difference. **P  0.001trol group was similar to the other groups (Table 1) with for the comparison with the TT genotype). GAPDH is glyceraldehyde-
no significant differences detected. Even though we did 3-phosphate dehydrogenase. Median is represented by bar.
not find any differences regarding their genotypic profile,
we analyzed cytokine expression in the patient and con-
trol group separately.
patients showed highest gene expression for the interme-Overall cytokine expression was different between the
diate-producer genotype at position –1082 and for theCAN patients and normal controls (Figs. 1, 2, and 3).
low-producer genotype at positions –819 and –592. High-In CAN patients, TGF-1 and TNF- expression was
est gene expression in controls was seen for high typesignificantly higher (1.6- and threefold, P  0.05, respec-
at position –1082 and for the low type at positions –819tively) and IL-10 expression was significantly lower (2.9-
and –592. None of these tendencies reach significantfold, P  0.05) when compared to normal controls.
levels.We then analyzed the expression levels according to
No significant differences were seen when TNF- pro-the underlying genotype. In patients with CAN, TGF-1
duction was classified according to the different geno-mRNA levels were not associated with the underlying
types and their predicted cytokine production patterngenotypes for either of the two TGF-1 SNPs at codon
(Fig. 3). Slightly higher expression levels were found for10 and codon 25 as illustrated in Figure 1. However,
in normal controls we found significant higher TGF-1 the intermediate-producer genotypes when compared to
levels for the high (TT) compared to the low (CC) pro- other genotypes in both groups.
ducer polymorphism at codon 10 (P  0.01). No differ-
ences were seen for codon 25.
DISCUSSIONWe were unable to find matching intrarenal cytokine
This is the first study combining cytokine SNP geno-production as suggested by their predicted phenotype
for any of the investigated IL-10 genotypes (Fig. 2). CAN typing with measurement of intrarenal cytokine expres-
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Fig. 3. Intrarenal tumor necrosis factor- (TNF-) mRNA expression
for pediatric renal transplant recipients with chronic allograft nephropa-
thy (CAN) (N  25) () and control individuals (N  28) () for
position308. Overall (ALL) TNF- expression was different between
CAN and controls. *P  0.05 for the comparison with controls. How-
ever, for the different TNF- genotypes and their predicted producing
phenotypes (High, Intermediate, Low) no significant differences were
found. GAPDH is glyceraldehyde-3-phosphate dehydrogenase. Median
is represented by bar.
A allele, and the G allele frequency was 88% or 89%,
respectively. Numbers from Gambia and Japan [28, 29]
are higher.
Our two patient groups, stable and CAD, showed no
significant differences in their genotypic and allelic distri-Fig. 2. Intrarenal interleukin-10 (IL-10) mRNA expression for pediat-
ric renal transplant recipients with chronic allograft nephropathy (CAN) bution when compared to controls. This is in contrast to
(N  25) () and control individuals (N  28) () for IL-10 position other groups that suggested an association of long-term1082 (A) and IL-10 position –819 and –592 (B). Overall (ALL) IL-10
kidney graft failure with high TGF-1 producer geno-expression was different between CAN and controls. *P  0.05 for the
comparison with controls. However, for the different IL-10 genotypes types [30]. The fact that there was a tendency toward
and their predicted producing phenotypes (High, Intermediate, Low).
fewer CAD patients in the IL-10 high producer groupNo significant differences were found. GAPDH is glyceraldehyde-3-
phosphate dehydrogenase. Median is represented by bar. for position –819 and –592, however, is consistent to what
was described by others [16]. However, since negative
findings need to be confirmed in enormous population
size, we cannot completely rule out a role of the investi-sion for TGF-1, IL-10, and TNF- in renal transplant
gated genotypes in CAN. Based on the differences foundrecipients. In our patient cohort, we were unable to con-
in our population (a small effect size of 0.06), a samplefirm a higher incidence of so-called high-producer cyto-
size including up to 2700 patients should have been inves-kine genotypes for any of the investigated cytokine in
tigated to detect differences with a power of 80% [31].the CAD patients. Furthermore, when intragraft expres-
A biologic reason for the discrepancy to other studiession in CAN patients was analyzed based on the geno-
could be that we only included children. It has beentype, no correlation was found. However, for control
suggested that the immune response in children is morespecimens there was a correlation for TGF-1 expression
reactive when compared to adults [32], which might ex-and the underlying genotype with significantly higher
plain the differences. Therefore, conclusions from ourTGF-1 expression in the homozygous so-called high-
study can only be made for a pediatric population andproducing T allele at codon 10.
are not necessarily extendable to adult renal recipients.Distribution of alleles and genotypes in our control
Thereby, our results do not contradict other opposinggroup was similar to what had been described by others
findings in adults.for TGF-1 [1, 2] and IL-10 [8, 15, 24, 25]. For TNF-,
The relationship between cytokine production and cy-we found a higher frequency of the low-producing G
tokine SNPs is based on in vitro studies [1, 7, 9, 10, 18,allele when compared to other studies in Caucasian pop-
19]. We tested whether patients or controls with a so-ulation [24–26]. Our numbers are closest to what has
called high-producing genotype would in fact havebeen recently published for African Americans and
higher intrarenal cytokine production. Our CAN pa-Asians [27] for which the distribution was 78% and 76%
for homozygous G, and 18% and 21% for heterozygous tients showed overall higher intragraft mRNA levels for
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TGF-1 and TNF- and lower intragraft mRNA levels the amount of tissue available from pediatric biopsies
makes this approach unfeasible and gene expressionfor IL-10 when compared to controls. The findings on
TGF-1 are consistent with earlier publications on CAN studies have been shown to provide excellent markers
to indicate graft response in rejection [37, 38].reporting higher TGF-1 levels in serum [33], urine [34],
and graft [4, 5, 35]. Superior long-term graft survival in The clinical value of cytokine polymorphisms has been
previously doubted [39]. Our data, for the first time eval-renal transplant patients has been associated with both
low [36] as well as high IL-10 levels [16]. The higher uating corresponding SNP distribution and intragraft
gene expression, indicate no relevant genotype-pheno-levels for TNF- were unexpected, especially since we
carefully excluded infection or acute rejection in this type correlation. We conclude that prospective genotyp-
ing for the examined SNPs in pediatric renal transplanta-patient cohort.
Analysis of cytokine expression levels by genotypes tion and potential modifications of immunosuppressive
strategies based on SNPs are not promising to preventshowed no differences for any of the investigated SNPs in
CAN. Interestingly, the same analysis in normal control CAN in children.
specimens revealed an association between production
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